CLINICAL TRIALS PROFILE FOR DENILEUKIN DIFTITOX
✉ Email this page to a colleague
All Clinical Trials for denileukin diftitox
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00006345 ↗ | Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma | Completed | Ligand Pharmaceuticals | Phase 2 | 1999-11-01 | RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox. PURPOSE: Phase II trial to study the effectiveness of dexamethasone in preventing side effects following treatment with denileukin diftitox in treating patients who have persistent or recurrent T-cell lymphoma. |
NCT00023530 ↗ | Blood and Marrow Transplant Clinical Research Network | Completed | Blood and Marrow Transplant Clinical Trials Network | N/A | 2001-09-01 | The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones. |
NCT00023530 ↗ | Blood and Marrow Transplant Clinical Research Network | Completed | National Heart, Lung, and Blood Institute (NHLBI) | N/A | 2001-09-01 | The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones. |
NCT00050999 ↗ | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients | Completed | Eisai Inc. | Phase 4 | 1995-06-01 | The purpose of this study is to compare the effectiveness of two dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma. |
NCT00051012 ↗ | Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients | Completed | Eisai Inc. | Phase 4 | 1995-09-01 | The purpose of this study is to provide an opportunity for patients who exhibit progressive disease while receiving placebo on the companion 93-04-11 study to receive ONTAK. It is also designed to determine the effectiveness of ONTAK in Cutaneous T-cell Lymphoma (CTCL) patients whose tumors do not express CD25. |
NCT00051025 ↗ | Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL) | Completed | Eisai Inc. | Phase 2 | 2000-05-01 | The purpose of this study is to look at the safety and effectiveness of ONTAK in previously treated patients with NHL. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for denileukin diftitox
Condition Name
Clinical Trial Locations for denileukin diftitox
Trials by Country
Clinical Trial Progress for denileukin diftitox
Clinical Trial Phase
Clinical Trial Sponsors for denileukin diftitox
Sponsor Name